



## Criteria for consideration of a drug

The criteria listed below are the factors that determine whether a drug is considered by the group. Points one to three may be the most applicable for considering medicines that are yet to be launched; it is upon these criteria that the formulary and managed entry subgroup will consider whether a recommendation on a drug should be made by the group.

### Criteria

1. The medicine will have a significant clinical and/or financial impact across the health economy of Greater Manchester. The medicine may impact primary or secondary care alone or affect both sectors.
2. The medicine requires a managed and co-ordinated approach to introduction on a wider basis than can be managed locally. For example, a co-ordinated approach may be necessary to ensure equity of access.
3. The use of a medicine will significantly change the way that services are configured.
4. The use of the medicine is controversial. For example, the evidence base may not be fully developed and there may be a difference of clinical opinion as to the use of the medicine, which cannot be resolved at local level.
5. There is evidence of differing approaches to managing access to an existing medicine which is adversely affecting equity of access or consistency of service provision, for example differing approaches to virement, shared care etc.
6. A NICE review is either not planned or there will be significant delay before the review is published.
7. A drug should not be considered by this group if it is considered to be an 'exceptional circumstance'. These cases would be dealt with as currently.
8. The cost will be high, or the size of the target population is large or is a significant subset of a large population.